It is very uncertain whether valproate changes adverse events ‐ Sedation At 8 weeks (secondary tolerability outcome) compared with risperidone (very low certainty).
Valproate showed no clear difference in individual adverse events ‐ Sedation At 3‐8 weeks (secondary… compared with placebo (high certainty).
Valproate showed no clear difference in dropout rate ‐ All‐cause (secondary acceptability outcome) At 5 ‐ 12… compared with risperidone (low certainty).
Valproate showed no clear difference in dropout rate ‐ All‐cause 3‐8 weeks (secondary acceptability outcome) compared with placebo (moderate certainty).
It is very uncertain whether valproate changes response rate at 4 weeks (primary efficacy outcome) compared with placebo (very low certainty).
It is very uncertain whether valproate changes number with any adverse event at 4 weeks (primary tolerability… compared with placebo (very low certainty).
It is very uncertain whether valproate changes individual adverse events ‐ Sedation At 4 weeks (secondary… compared with placebo (very low certainty).
Lithium showed no clear difference in efficacy: remission (categorical) YMRS ≤ 12 and no increase in MADRS… compared with valproate (moderate certainty).
Lithium showed no clear difference in acceptability: total withdrawals compared with valproate (high certainty).
Lithium leads to higher adverse event: tremor compared with valproate (high certainty).
Lithium leads to lower adverse event: somnolence compared with valproate (high certainty).
Lithium showed no clear difference in adverse event: nausea compared with valproate (moderate certainty).
Lithium showed no clear difference in efficacy: response (categorical) YMRS/SADS‐C decrease ≥ 50% by end… compared with valproate (moderate certainty).